The London Health Sciences Centre has released a statement in support of recent reviews after diluted chemotherapy drugs were administered to cancer patients, but says changes have already been implemented.
Murray Glendining, acting president and CEO at LHSC, said the hospital supports any review to ensure safeguards are in place to prevent a repeat of the issue.
"Similar to the Theissen report, the Standing Committee's report released late yesterday highlights breakdowns in the system and also recommends further actions across several stakeholders to strengthen treatment safeguards."
The statement goes on to say the hospital has the fullest confidence in its pharmacy and cancer teams in ensuring safety and quality, and that changes have already been made.
"Last year, LHSC implemented process changes to safeguard against any similar incident occurring and we will continue to support any further reviews that may be conducted surrounding the chemotherapy dosage issue."
Recommendations released
The Standing Committee on Social Policy released new recommendations on Tuesday after diluted chemotherapy drugs were administered to cancer patients last year.
From April to October 2013, the committee collected sworn testimony from patients who received watered down chemotherapy drugs.
Some patients at LHSC and Windsor Regional Hospital were among the over 1,200 people who received the diluted treatment.
Among the measures proposed to ensure this doesn't happen again include changes to the way group purchasing is operated and ensuring Health Canada brings accreditation to companies supplying the drugs.
